AKT1 and lung carcinoma: Since RASSF2 is inactivated at a high frequency in lung cancer [9, 11, 19] and loss of RASSF2 expression is associated with an increase in activated AKT (Figure 5 and [18], a targeted therapeutic approach using agents against AKT, perhaps in combination with cytotoxic therapy, may prove more successful in at least a subset of lung cancer patients.